Pooled analysis of two studies evaluating efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis
Eugene McLaurin,1 Mark Bergmann,2 Abhijit Narvekar,3 Adeniyi Adewale,3 Paul Gomes,4 Gail Torkildsen5 1Department of Ophthalmology, Total Eye Care, PA, Memphis, TN, 2Department of Ophthalmology, Apex Eye, Cincinnati, OH, 3Department of Ophthalmology, Alcon Research Ltd, Fort Worth, TX, 4Department o...
Guardado en:
Autores principales: | McLaurin E, Bergmann M, Narvekar A, Adewale A, Gomes P, Torkildsen G |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2017
|
Materias: | |
Acceso en línea: | https://doaj.org/article/bcc1397ea6544626bbee7cd3c23cfce1 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Pharmacokinetics and safety of olopatadine hydrochloride 0.77% in healthy subjects with asymptomatic eyes: data from 2 independent clinical studies
por: Meier E, et al.
Publicado: (2017) -
Safety of cetirizine ophthalmic solution 0.24% for the treatment of allergic conjunctivitis in adult and pediatric subjects
por: Malhotra RP, et al.
Publicado: (2019) -
Efficacy and safety of olopatadine hydrochloride 0.77% in patients with allergic conjunctivitis using a conjunctival allergen-challenge model
por: Torkildsen G, et al.
Publicado: (2015) -
Efficacy of 0.05% epinastine and 0.1% olopatadine for allergic conjunctivitis as seasonal and preseasonal treatment
por: Mizoguchi T, et al.
Publicado: (2017) -
Phase III trials examining the efficacy of cetirizine ophthalmic solution 0.24% compared to vehicle for the treatment of allergic conjunctivitis in the conjunctival allergen challenge model
por: Meier EJ, et al.
Publicado: (2018)